Friday, April 22, 2011
Marinus Pharmaceuticals Inc., of Branford, Conn., announced the start of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of post-traumatic stress disorder (PTSD). The company said that ganaxolone modulates inhibitory GABA-A receptors, possibly at a specific neurosteroid recognition site. Neurosteroid levels have been implicated in both the severity and treatment outcome in PTSD patients. The trial will take place in the U.S. and is expected to enroll about 120 PTSD patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.